{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"6"}]}],"title":"Improved in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"18"}]}],"title":"Stable in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"8"}]}],"title":"Worsened in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"16"}]}],"title":"Improved in coughing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"15"}]}],"title":"Stable in coughing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"1"}]}],"title":"Worsened in coughing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-coughing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"}]}],"title":"Improved in hemoptysis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"36"},{"groupId":"OG006","value":"31"}]}],"title":"Stable in hemoptysis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Worsened in hemoptysis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-hemoptysis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"}]}],"title":"Improved in sore mouth"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"26"}]}],"title":"Stable in sore mouth"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"2"}]}],"title":"Worsened in sore mouth"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-sore mouth"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"3"}]}],"title":"Improved in dysphagia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"27"}]}],"title":"Stable in dysphagia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"2"}]}],"title":"Worsened in dysphagia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-dysphagia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"9"}]}],"title":"Improved in peripheral neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"16"}]}],"title":"Stable in peripheral neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"7"}]}],"title":"Worsened in peripheral neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-peripheral neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"4"}]}],"title":"Improved in alopecia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"21"}]}],"title":"Stable in alopecia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"}]}],"title":"Worsened in alopecia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-alopecia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"13"}]}],"title":"Improved in chest pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"17"}]}],"title":"Stable in chest pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"}]}],"title":"Worsened in chest pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing-chest pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"9"}]}],"title":"Improved in arm or shoulder pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"19"}]}],"title":"Stable in arm or shoulder pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"4"}]}],"title":"Worsened in arm or shoulder pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Missing- arm or shoulder pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"9"}]}],"title":"Improved in pain in other parts"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"10"}]}],"title":"Stable in pain in other parts"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"}]}],"title":"Worsened in pain in other parts"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"}]}],"title":"Missing-Pain in other parts"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"32"}],"units":"Participants"}],"description":"EORTC QLQ-LC13 is the lung cancer module of EORTC QLQ-C30 and includes questions specific to the disease associated symptoms (dyspnea, cough, hemoptysis, and site specific pain), treatment-related symptoms (sore mouth, dysphagia, neuropathy and alopecia), and analgesic use of lung cancer patients. The scale was transformed to a range of 0 to 100 using standard EORTC algorithm. Higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","groups":[{"description":"Treatment-naïve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"EXP-1 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG001","title":"EXP-2 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"EXP-3 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"EXP-4 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"EXP-5 (Phase 2)"},{"description":"Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG005","title":"EXP-6 (Phase 2)"},{"description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.","id":"OG006","title":"DDI Sub-study"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patient reported outcome (PRO) evaluable analysis set included all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","title":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study)","type":"SECONDARY","unitOfMeasure":"Participants"}